Niraparib Shows Favorable Outcomes in Germline BRCA+ Recurrent Ovarian Cancer

An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.

A population of patients with germline BRCA-mutated (gBRCA) recurrent ovarian cancer derived overall survival (OS) benefit from niraparib compared with placebo, according to Ursula A. Matulonis, MD.

Matulonis, chief of the Division of Gynecologic Oncology, Brock-Wilson Family Chair, and institute physician at Dana-Farber Cancer Institute and professor of Medicine at Harvard Medical School, spoke with CancerNetwork® at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer regarding the final OS analysis of the phase 3 ENGOT-OV16/NOVA trial (NCT01847274).

The median OS in the gBRCA cohort following treatment with niraparib and placebo, respectively, was 40.9 months vs 38.1 months (HR, 0.85; 95% CI, 0.61-1.20). In the non-gBRCA cohort, the median OS was 31.0 months vs 34.8 months with niraparib and placebo, respectively (HR, 1.06; 95% CI, 0.81-1.37).


[I presented] the original OS data for NOVA in 2021 at the Society of Gynecologic Oncology Annual Meeting. At that point, about 17% [of patients had] missing data for [OS]. The FDA actually strongly recommended that survival status be obtained for as many patients as possible.

[With] these newest OS data—the final OS analysis—98% of patients have known [OS] status, so that missing data of 17% went down to about 2%. What I presented is that for patients with a gBRCA mutated status, the hazard ratio is 0.85 in favor of niraparib vs placebo. The OS is about 41 months for patients [in the] gBRCA [population] receiving niraparib vs about 38 months for patients receiving placebo. It's important that the OS was a secondary end point and not powered for.

In the non-gBRCA patient population, the hazard ratio is 1.06 in favor of placebo. Patients in that group receiving placebo had an OS of about 41 months, and for patients who received niraparib, it was just around 38 months or so.


Matulonis UA, Herrstedt J, Mahner S, et al. Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase 3 trial of niraparib in patients with recurrent ovarian cancer. Presented at Society of Gynecological Oncology 2023 Virtual Annual Meeting on Women’s Cancer; March 25-28, 2023; Tampa, FL.

Related Videos
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
For clinicians practicing in the community, constant communication and education from those in institutions may help to produce the best quality of care for patients with multiple myeloma.
Ashley E. Rosko, MD, specializes in multidisciplinary care for elderly patients with multiple myeloma, and how to make treatment most accessible to them.
At first relapse, novel therapies are offered to patients with multiple myeloma at The Ohio State University Comprehensive Cancer Center-The James.